BioNTech SE Cash Flow Conversion Efficiency
BioNTech SE cash flow conversion efficiency. Based on the latest financial reports, BioNTech SE (22UA) has a cash flow conversion efficiency ratio of -0.023x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-421.00 Million ≈ $-492.19 Million USD) by net assets (€18.70 Billion ≈ $21.86 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BioNTech SE (2017–2025)
Cash flow conversion efficiency of BioNTech SE from 2017 to 2025. This chart illustrates how BioNTech SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 22UA stock price for real-time trading data and today's change.
BioNTech SE Cash Flow Conversion Ratio Explained
BioNTech SE cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BioNTech SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioNTech SE ranked by their cash flow conversion efficiency. Also see 22UA stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China United Network Communications Ltd
SHG:600050
|
0.087x |
|
Canon Inc
F:CNNA
|
0.045x |
|
First Financial Holding Co Ltd
TW:2892
|
0.064x |
|
CHINA SHENHUA EN.A ADR/4
F:IKFC
|
N/A |
|
China Development Financial Holding Corp
TW:2883
|
-0.072x |
|
Fidelity National Information Services Inc
NYSE:FIS
|
0.076x |
|
CLP HLDGS LTD ADR/1 HD 5
F:CLP1
|
N/A |
|
Yihai Kerry Arawana Holdings Co Ltd
SHE:300999
|
0.138x |
Annual Cash Flow Conversion Efficiency for BioNTech SE (2017–2025)
The table below shows the annual cash flow conversion efficiency of BioNTech SE from 2017 to 2025. Review 22UA free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €19.22 Billion ≈ $22.48 Billion |
€456.00 Million ≈ $533.11 Million |
0.024x | +121.68% |
| 2024-12-31 | €19.41 Billion ≈ $22.69 Billion |
€207.70 Million ≈ $242.82 Million |
0.011x | -95.97% |
| 2023-12-31 | €20.25 Billion ≈ $23.67 Billion |
€5.37 Billion ≈ $6.28 Billion |
0.265x | -60.81% |
| 2022-12-31 | €20.06 Billion ≈ $23.45 Billion |
€13.58 Billion ≈ $15.87 Billion |
0.677x | +805.01% |
| 2021-12-31 | €11.89 Billion ≈ $13.90 Billion |
€889.70 Million ≈ $1.04 Billion |
0.075x | +860.15% |
| 2020-12-31 | €1.37 Billion ≈ $1.60 Billion |
€-13.50 Million ≈ $-15.78 Million |
-0.010x | +97.55% |
| 2019-12-31 | €493.49 Million ≈ $576.94 Million |
€-198.50 Million ≈ $-232.07 Million |
-0.402x | -82.41% |
| 2018-12-31 | €267.00 Million ≈ $312.15 Million |
€-58.88 Million ≈ $-68.83 Million |
-0.221x | -120.22% |
| 2017-12-31 | €-48.21 Million ≈ $-56.36 Million |
€-52.56 Million ≈ $-61.45 Million |
1.090x | -- |
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic tr… Read more